Ewe Kheng Huat, executive director of PhAMA, the Malaysian association for innovative companies, describes the current market environment for innovative medicines in Malaysia, from the difficulties to enter the Malaysian market to the great opportunities the country can offer in terms of clinical research and shared services.
We believe the country can be an attractive hub for clinical trials in the region and the government should focus its efforts on bringing more innovation, technology transfers and technology applications to foster better investments and partnerships.
